Neuroscience and Biobehavioral Reviews
May 1, 2025
Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.
36 citations
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intensity and quality of psychedelic experiences plays a significant role in mediating therapeutic effects. However, the strength of this association across diagnoses and treatment settings remains underexplored. We searched MEDLINE, Embase, and PsycINFO...
International Journal of Neuropsychopharmacology
February 12, 2025
*Danilo De Gregorio, Carolina Giulia Ferroni, Noemi Nicosia et al.
Abstract Introduction Alcohol use disorder (AUD) is a major problem that causes significant health and social problem. Pharmacological treatments for AUD are limited in their effectiveness, and new drugs are required (ref). Recently, the potential use of psychedelics as novel therapies in treating mental diseases has come to the forefront in psychiatry. For instance, lysergic acid diethylamide...
Addiction
January 30, 2025
Theodore Piper, Francesca Small, Michael Kelleher et al.
27 citations
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
International review of neurobiology
2025
Caitlin M. DuPont, Matthew W. Johnson
6 citations
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced...
Current Psychiatry Reports
December 1, 2024
Daan de Jonge, Pim B. van der Meer, Cornelis Kramers et al.
2 citations
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorder (MDD). We describe limitations of psychedelic research and posit methodological considerations when designing a trial in patients with both disorders. In AUD, a growing evidence base for psilocybin treatment shows a promising beneficial and...
Pharmaceuticals (Basel, Switzerland)
November 5, 2024
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al.
4 citations
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...
European Addiction Research
September 25, 2024
Ioanna A. Vamvakopoulou, David Nutt
13 citations
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...
The Journal of analytical psychology
September 1, 2024
Robert McDonnell, John Moriarty, Ian Mc Cabe et al.
2 citations
Alcoholics Anonymous (AA) is an established resource for people suffering from alcohol use disorder (AUD). However, Bill Wilson, the co-founder of AA, in his second letter to Jung referred to its low success rate. One evidence-based alternative, dating back to the 1950s, is the clinical use of lysergic acid diethylamide (LSD) for treating AUD. Bill Wilson was a strong advocate of using LSD as a...
Current Medical Research and Opinion
February 1, 2024
Dakota Sicignano, Adrían V. Hernández, Benjamin Schiff et al.
19 citations
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic literature search of PubMed was completed from 1960 to 9/9/2023. We pooled randomized controlled trials comparing psychedelics to control therapy for the treatment of alcohol use disorder. At the first recorded follow-up, LSD [n = 3, Odds Ratio (OR)...